Jazz Pharmaceuticals, Inc



Fast Facts Founded: 2003 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative products NASDAQ Symbol: JAZZ for unmet medical needs in neurology and psychiatry. Headquarters: Palo Alto, California Jazz Pharmaceuticals has an unwavering commitment to improving care for patients with serious neurological and psychiatric conditions through Employees: 220 innovative products and distinctive, valuable programs for patients and physicians. Collaboration with key constituencies, including physicians, 2007 Revenues: $65 million patients and industry partners, facilitates innovation and ensures therapeutics and new product candidates fulfill important medical needs. Products XYREM® (sodium oxybate) approved Jazz Pharmaceuticals has built its pipeline by expertly leveraging novel for the treatment of excessive daytime formulations and drug delivery technologies to advance known and/or well- sleepiness and cataplexy, in patients characterized compounds. This lower-risk model enables the company to with Narcolepsy. maintain its focus on patient care with the goal of improving product efficacy, LUVOX CR® (fluvoxamine maleate) reducing adverse side effects and increasing patient compliance relative to Extended Release Capsules approved existing therapies. for the treatment of Social Anxiety Disorder and Obsessive Compulsive Products & Pipeline Disorder. The company currently markets two products and is developing a portfolio of Commercial Operations products for the treatment of serious neurological and psychiatric conditions, including fibromyalgia, restless legs syndrome, recurrent acute seizures, Jazz Pharmaceuticals markets XYREM epilepsy and bipolar disorder. The company built its portfolio through a and LUVOX CR in the United States combination of internal development and acquisition/in-licensing activities. through its specialty sales force. UCB markets XYREM in Europe and Valeant Jazz Pharmaceuticals’ experienced specialty sales force promotes products Canada Ltd. markets XYREM in in the U.S., and the company has formed successful partnerships with leading Canada. pharmaceutical companies for product marketing and sales in international markets. Key Pipeline Products JZP-6: Fibromyalgia JZP-7: Restless Legs Syndrome JZP-8: Recurrent Repetitive Clinical Development Marketed Acute Seizures JZP-4: Epilepsy & Bipolar Disorder

Obsessive Compulsive Disorder and Social Anxiety Disorder Analyst Coverage Barclays Capital Cataplexy and Excessive Daytime Sleepiness in Narcolepsy Lazard Leerink Swann JZP-6 Fibromyalgia Phase III Natixis Bleichroeder Pacific Growth Equities JZP-7 Restless Legs Syndrome Phase II Investor Relations Contact JZP-8 Recurrent Acute Repetitive Seizures Phase II Ph: +1-650-496-3777 JZP-4 Epilepsy/Bipolar Disorder Phase I [email protected] Management Jazz Pharmaceuticals’ management team Products has a proven track record of successfully developing and commercializing medical treatments that deliver results. Bruce C. Cozadd Executive Chairman LUVOX CR®, a selective serotonin reuptake inhibitor (SSRI), is approved for the treatment Samuel R. Saks, M.D. CEO of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD), two difficult-to- treat, underdiagnosed and undertreated anxiety disorders. SAD affects approximately 15 Robert M. Myers President million American adults, and OCD affects approximately 2.2 million American adults. Carol A. Gamble SVP, General Counsel & Corporate Secretary Janne L. T. Wissel SVP, Chief Regulatory Officer & Chief Compliance Officer XYREM® (sodium oxybate) is the only FDA-approved therapy for the treatment of the two Michael DesJardin SVP, Product Development most common daytime symptoms of narcolepsy, excessive daytime sleepiness (EDS) and Mark G. Eller cataplexy. Narcolepsy is a chronic and debilitating neurological sleep disorder caused by the SVP, Research & Clinical Development brain’s inability to regulate sleep-wake cycles. Narcolepsy is estimated to affect 1 in 2,000 Diane R. Guinta, Ph.D. people in the U.S., but fewer than 85,000 are diagnosed. VP, Clinical Research & Development P.J. Honerkamp Product Development Candidates VP, Deputy General Counsel Jazz Pharmaceuticals’ development-stage product candidates were selected based on a Edwin W. Luker VP, Sales clear medical need, and each is advanced to the next phase of development only after Heather McGaughey passing rigorous proof-of-concept evaluation in early studies. VP, Human Resources Joel M. Rothman The company’s most advanced agent in development is JZP-6 (sodium oxybate) for the VP, Development Operations treatment of fibromyalgia, a chronic pain condition affecting approximately 6-12 million Americans. Two phase III clinical trials of JZP-6 are underway, and the company anticipates Board of Directors submitting a New Drug Application to the U.S. Food and Drug Administration by the end of 2009. E. Alex Albert Kohlberg Kravis Roberts & Co. L.P. Samuel D. Colella Jazz Pharmaceuticals is also conducting phase II clinical trials for JZP-8, an intranasal Versant Ventures formulation of clonzepam for the treatment of recurrent acute repetitive seizures. This trial is Bruce C. Cozadd expected to conclude during 2008. Jazz Pharmaceuticals’ key development candidates also Jazz Pharmaceuticals include JZP-7, designed to be a once-daily transdermal gel for the treatment of restless legs Bryan C. Cressey syndrome, and JZP-4, a controlled release formulation of a new chemical entity with a similar Thoma Cressey Bravo, Inc. structure to Lamictal® for the treatment of epilepsy and bipolar disorder. Consistent with its Michael W. Michelson commitment to addressing areas of unmet neurological and psychiatric need, the company is Kohlberg Kravis Roberts & Co. L.P. identifying and evaluating product candidates with the goal of providing innovative solutions James C. Momtazee to these patients in need. Kohlberg Kravis Roberts & Co. L.P. Kenneth W. O’Keefe Commitment Beecken Petty O’Keefe & Company Samuel R. Saks, MD Jazz Pharmaceuticals has supported patient advocacy groups to further public education and Jazz Pharmaceuticals to develop unique resources for patients and physicians, including diagnostic screening tools, Alan M. Sebulsky disease education websites and a patient assistance program. The programs are intended Apothecary Capital LLC to increase awareness and improve knowledge of often misunderstood conditions, such James B. Tananbaum, MD as narcolepsy, OCD and SAD, and to help ensure that patients receive accurate diagnosis Prospect Venture Partners and access to effective treatment. Jazz Pharmaceuticals also seeks direct feedback from Nathaniel M. Zilkha physicians through occassional scientific and medical advisory board meetings and consults Kohlberg Kravis Roberts & Co. L.P with key opinion leaders in neurology and psychiatry to gain valuable insight into important unmet medical needs.

Please visit Jazz Pharmaceuticals at www.jazzpharmaceuticals.com.